US20040082666A1 - Inhibitor of monoamine uptake - Google Patents

Inhibitor of monoamine uptake Download PDF

Info

Publication number
US20040082666A1
US20040082666A1 US10/468,553 US46855303A US2004082666A1 US 20040082666 A1 US20040082666 A1 US 20040082666A1 US 46855303 A US46855303 A US 46855303A US 2004082666 A1 US2004082666 A1 US 2004082666A1
Authority
US
United States
Prior art keywords
methyl
phenyl
oxy
aminopropane
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/468,553
Other languages
English (en)
Inventor
Edward Mattiuz
John-Michael Sauer
William Wheeler
David Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040082666(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/468,553 priority Critical patent/US20040082666A1/en
Publication of US20040082666A1 publication Critical patent/US20040082666A1/en
Priority to US11/125,348 priority patent/US7384983B2/en
Priority to AU2007201684A priority patent/AU2007201684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Atomoxetine ( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride, is a selective norepinephrine uptake inhibitor that is being investigated clinically for the treatment of attention deficit/hyper-activity disorder.
  • Duloxetine (+)-N-methyl 3-(1-naphthalenyloxy)-3-(2-thienyl)-1-aminopropane hydrochloride, inhibits the uptake of both norepinephrine and serotonin and is presently in clinical evaluation for the treatment of depression.
  • These compounds are among many 3-aryloxy-3-substituted-1-aminopropanes taught in U.S. Pat. Nos.
  • This invention also provides a pharmaceutical formulation that comprises, in association with a pharmaceutically acceptable carrier, diluent or excipient, a compound of Formula I.
  • the present invention provides a method for inhibiting the uptake of norepinephrine and serotonin in mammals comprising administering to a mammal in need of such inhibition a pharmaceutically effective amount of a compound of Formula I.
  • a further embodiment of this invention is a method for inhibiting the uptake of norepinephrine and serotonin in mammals for treating a variety of disorders that have been linked to decreased neurotransmission of serotonin and/or norepinephrine in mammals.
  • disorders include: depression, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, alcoholism, tobacco abuse, panic disorder, anxiety, general pain, post-traumatic syndrome, memory loss, dementia of aging, social phobia, attention deficit/hyperactivity disorder, psoriasis, oppositional defiant disorder, conduct disorder, borderline personality disorder, obsessive compulsive disorder, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, allergic rhinitis, cold symptoms, narcolepsy, incontinence, trichotillomania, trigeminal neuralgia, dental pain or temperomandibular joint dysfunction pain. Any of these methods employ a compound of Formula I.
  • This invention also provides the use of a compound of Formula I for the manufacture of a medicament for the inhibition of norepinephrine and serotonin uptake. Additionally, this invention provides a pharmaceutical formulation adapted for the inhibition of norepinephrine and serotonin uptake containing a compound of Formula I or a metabolic precursor thereof.
  • the present invention further provides a method for the preparation of a compound of Formula I comprising the steps of:
  • the present invention also provides a process for the preparation of a compound of Formula I comprising the steps of:
  • the compound of Formula I is generally referred to as R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane. Because this compound is an amine, it is basic in nature and accordingly reacts with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. It is preferable to convert the free amine to a pharmaceutically acceptable acid addition salt for ease of handling and administration.
  • Acids commonly employed to form salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
  • organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like.
  • salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogen-phosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phen
  • the compound of Formula I is chiral, and may be prepared by chiral chromatography of the racemic or enantiomerically enriched forms of a compound of Formula I, or fractional crystallization of salts prepared from racemic or enantiomerically enriched free amine and a chiral acid.
  • the free amine may be reacted with a chiral auxiliary and the enantiomers separated by chromatography followed by removal of the chiral auxiliary to regenerate the free amine.
  • separation of enantiomers may be performed at any convenient point in the synthesis of the compounds of the invention.
  • the compounds of the invention are prepared beginning with chiral starting material.
  • the present invention provides a method for the inhibition of serotonin and norepinephrine uptake. These mechanisms are operable in mammals, and the preferred mammal is human.
  • R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane may be conveniently prepared as illustrated in the following scheme where “Pg” is an oxygen protecting group and “X” is either chloro or NHMe.
  • the requisite phenols of formula (i) may be prepared from commercially available methylhydroquinone by introducing an appropriate oxygen-protecting group by standard synthetic methods.
  • Suitable oxygen protecting groups for phenols are well known to the skilled artisan and are described in Greene and Wuts ( Protective Groups in Organic Synthesis, Third Edition, John Wiley and Sons, New York (1999)).
  • Preferred protecting groups for the process of the present invention are alkanoyl esters and silyl ethers.
  • Particularly preferred oxygen protecting groups are acetyl, tert-butoxycarbonyl, and tert-butyldimethylsilyl. The use of tert-butoxycarbonyl is especially preferred.
  • a solution of an equivalent of phenol (i) and an equivalent of alcohol (v) are combined in a suitable solvent with from about 1.0 to about 1.1 equivalents of triphenylphosphine.
  • Suitable solvents include any solvent that dissolves a sufficient amount of the reactants to allow the reaction to occur without significantly interfering with the desired reaction.
  • Suitable solvents include dioxane, diethyl ether, and tetrahydrofuran.
  • a preferred solvent is tetrahydrofuran.
  • This solution is cooled to from about ⁇ 5° C. to about 5° C., preferably from about 0° C. to about 5° C.
  • the reaction mixture is maintained under an inert atmosphere of either nitrogen or argon.
  • About 1.0 to about 1.5 equivalents, preferably about 1.1 equivalents, of a dialkyl azodicarboxylate, preferably diisopropyl azodicarboxylate, are added to the reaction mixture.
  • the resulting mixture is then stirred for from about 1 hour to about 24 hours and then the desired aryl ether is isolated and purified by standard techniques.
  • a source of iodide ion Any source of iodide ion that is compatible with the chosen solvent and aryl ether (ii) is acceptable.
  • Preferred sources of iodide ion include sodium and potassium iodide.
  • Sodium iodide is a preferred source of iodide ion.
  • the resulting aryl ether (iii) is isolated and purified by standard techniques.
  • Methylamine may be added as a gas, condensed into the reaction mixture as a liquid, or added as an aqueous solution to the reaction mixture. Once the addition is complete, the reactants are stirred together for from about one hour to about 24 hours. The desired amine is then isolated and purified by standard techniques.
  • Acetic anhydride (4.73 gm, 4.37 mL, 46.3 mMol) was added dropwise to a mixture of 4-hydroxy-2-methylphenol (5 gm, 46.3 mMol) and cesium carbonate (15.1 gm, 46.3 mMol) in acetonitrile (50 mL). After stirring overnight, the mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with 5:1 pentane:ethyl acetate. Fractions containing product were combined and concentrated under reduced pressure to provide 0.24 gm (3%) of the desired compound.
  • MS(FAB): m/z 172.0 (10%), 170 (23%), 154 (10%), 132 (25%), 117 (5%), 107 (100%), 79 (54%), 77 (45%), 51 (19%).
  • the reaction mixture was cooled at 0° C., and a solution of diisopropylazadicarbox-ylate (76 ml, 365 mmol,) in dry tetrahydrofuran (100 mL) was added over 6 hours.
  • the reaction mixture was stirred for an additional two hours at 0° C. and was then allowed to warm gradually to room temperature.
  • the reaction mixture was further stirred at room temperature for 24 hours and the reaction mixture was concentrated under reduced pressure.
  • the residue was treated with 2 L of 9:1 pentane:ethyl acetate.
  • the resulting suspension was stored at ⁇ 20° C. for 24 hours and the insoluble materials were removed by filtration.
  • EA Calcd for C 17 H 21 NO 2 -HCl: C, 66.33, H, 7.20. N, 4.55, Cl, 11.52. Found: C, 66.23, H, 7.22, N, 5.37, Cl, 11.23.
  • All of the compounds concerned are orally available and are normally administered orally, and so oral administration is preferred.
  • oral administration is not the only route or even the only preferred route.
  • transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine.
  • Compounds of Formula I may also be administered by the percutaneous, intravenous, intramuscular, intranasal or intrarectal route, in particular circumstances.
  • the route of administration may be varied in any way, limited by the physical properties of the drugs, the convenience of the patient and the caregiver, and other relevant circumstances ( Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990)).
  • the pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art.
  • the carrier or excipient may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art.
  • the pharmaceutical composition may be adapted for oral, inhalation, parenteral, or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solutions, suspensions, or the like.
  • the compounds of the present invention may be administered orally, for example, with an inert diluent or capsules or compressed into tablets.
  • the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like.
  • These preparations should contain at least 4% of the compound of the present invention, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit.
  • the amount of the compound present in compositions is such that a suitable dosage will be obtained.
  • Preferred compositions and preparations according to the present invention may be determined by a person skilled in the art.
  • the tablets, pills, capsules, troches, and the like may also contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and sweetening agents such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring.
  • binders such as microcrystalline cellulose, gum tragacanth or gelatin
  • excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like
  • lubricants such as magnesium stearate or Sterotex
  • glidants such as colloidal silicon dioxide
  • sweetening agents such as sucrose or saccharin may be added or
  • the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil.
  • a liquid carrier such as polyethylene glycol or a fatty oil.
  • Other dosage unit forms may contain other various materials that modify the physical form of the dosage unit, for example, as coatings.
  • tablets or pills may be coated with sugar, shellac, or other coating agents.
  • a syrup may contain, in addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
  • a formulation useful for the administration of R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride (atomoxetine), a metabolic precursor of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane, comprises a dry mixture of R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride with a diluent and lubricant.
  • a starch such as pregelatinized corn starch, is a suitable diluent and a silicone oil, such as dimethicone, a suitable lubricant for use in hard gelatin capsules.
  • Suitable formulations are prepared containing about 0.4 to 26% R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride, about 73 to 99% starch, and about 0.2 to 1.0% silicone oil.
  • the compounds of the present invention may be incorporated into a solution or suspension. These preparations typically contain at least 0.1% of a compound of the invention, but may be varied to be between 0.1 and about 90% of the weight thereof. The amount of the compound of formula I present in such compositions is such that a suitable dosage will be obtained.
  • the solutions or suspensions may also include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Preferred compositions and preparations are able to be determined by one skilled in the art.
  • the compounds of the present invention may also be administered topically, and when done so the carrier may suitably comprise a solution, ointment, or gel base.
  • the base for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bees wax, mineral oil, diluents such as water and alcohol, and emulsifiers, and stabilizers.
  • Topical formulations may contain a concentration of the formula I, or its pharmaceutical salt, from about 0.1 to about 10% w/v (weight per unit volume).
  • R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane may be obtained by the conversion, for example by enzymatic or acid catalysis, of metabolic precursors of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane.
  • a metabolic precursor of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane is a compound that is converted to R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane in vivo after administration of the metabolic precursor to a mammal.
  • administering may also be accomplished by administering a metabolic precursor of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane.
  • a metabolic precursor of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane would be administered in dosage amounts that would produce effective inhibition of serotonin and norepinephrine uptake without causing harmful or untoward side effects.
  • Metabolic precursors of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane include carboxylic acid esters, sulfonate esters, amino acid esters, and ethers of the hydroxy moiety of Formula I. Furthermore, it has been discovered that R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane can be obtained by the enzymatic conversion of R-( ⁇ )-N-methyl 3-((2-methyl-phenyl)oxy)-3-phenyl-1-aminopropane, atomoxetine, in vivo.
  • a preferred method of systemic administration of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphen-yl)oxy)-3-phenyl-1-aminopropane is the oral administration to mammals of R-( ⁇ )-N-methyl 3-((2-methyl-phenyl)oxy)-3-phenyl-1-aminopropane hydrochloride, atomoxetine.
  • systemic administration of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane may be preferably accomplished by oral administration to mammals of R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride, atomoxetine, as a metabolic precursor of R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)-oxy)-3-phenyl-1-aminopropane.
  • Sprague-Dawley rats (Harlan or Charles River) weighing 270-300 grams are surgically implanted with microdialysis probes under chloral hydrate/pentobarbital anesthesia (170 and 36 mg/kg i.p. in 30% propylene glycol, 14% ethanol) as described by Perry and Fuller. (Perry and Fuller, Effect of fluoxetine on serotonin and dopamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan, Life Sci., 50, 1683-90 (1992)).
  • a David Kopf stereotaxic instrument is used to implant the probe unilaterally in the hypothalamus at coordinates rostral -1.5 mm, lateral ⁇ 1.3 mm, and ventral ⁇ 9.0 mm (Paxinos and Watson, 1986).
  • rats are placed in a large plastic bowl with a mounted liquid swivel system (CMA/120 system for freely moving animals, Bioanalytical Systems, West Lafayette, Ind.).
  • Filtered artificial cerebrospinal fluid (CSF) 150 mM NaCl, 3.0 mM KCl, 1.7 mnM CaCl2, and 0.9 mM MgCl2
  • CSF cerebrospinal fluid
  • the output dialysate line is fitted to a tenport BPLC valve with a 20 ⁇ l loop. At the end of each 30 minute sampling period, dialysate collected in the loop is injected on an analytical column (Spherisorb 3 ⁇ ODS2, 2 ⁇ 150 mm, Keystone Scientific).
  • the mobile phase for the amine column is delivered with a flow programmable pump at an initial flow rate of 0.2 ml/min increasing to 0.3 ml/min at 5 min then decreasing back to 0.2 ml/min at 26 min with a total run time of 30 min.
  • Flow programming is used to elute the 5-HT within a 25 min time period.
  • the electrochemical detector (EG&G, Model 400) for the amine column is set at a potential of 400 mV and a sensitivity of 0.2 nA/V. Basal levels are measured for at least 90 minutes prior to drug administration.
  • the drugs are prepared in filtered deionized water (volume 0.25-0.3 ml) for administration at the desired doses.
  • CYP2D6 is an enzyme with genetic polymorphism resulting in at least 2 populations of individuals with either active or poor metabolic capabilities. The majority of people are designated “extensive metabolizers” (EM) and possess “normal” CYP2D6 activity. Mutations or deletion of the CYP2D6 gene results in a minority of people (5% to 10% of Caucasians; 1% of Asians) who are known as “poor metabolizers” (PM) of CYP2D6 substrates.
  • EM exclusive metabolizer
  • PM poor metabolizers
  • Radiolabeled [3- 14 C]-R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane was supplied as 20-mg capsules of R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride containing a sufficient quantity of [3- 14 C]-R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride to provide a dose of approximately 3.7 Mbq (100 ⁇ Ci).
  • a second 20-mg capsule was administered with 240 mL of water. This evening dose was administered at least 30 minutes after a low residue evening meal.
  • a capsule of 20-mg R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride containing 100 ⁇ Ci [3-14C]-R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride was given orally with 240 mL of water 30 minutes after completion of a standardized breakfast.
  • the primary metabolite of R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride produced by both CYP2D6 EM and PM subjects is R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane.
  • the EM subjects metabolized 86.5% of R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride to R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane.
  • the PM subjects metabolized 40% of R-( ⁇ )-N-methyl 3-((2-methylphenyl)oxy)-3-phenyl-1-aminopropane hydrochloride to R-( ⁇ )-N-methyl 3-((2-methyl-4-hydroxyphen-yl)oxy)-3-phenyl-1-aminopropane.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US10/468,553 2001-03-06 2002-02-20 Inhibitor of monoamine uptake Abandoned US20040082666A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/468,553 US20040082666A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake
US11/125,348 US7384983B2 (en) 2001-03-06 2005-05-09 Inhibitor of monoamine uptake
AU2007201684A AU2007201684A1 (en) 2001-03-06 2007-04-17 Inhibitor of monoamine uptake

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
US60273730 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake
US10/468,553 US20040082666A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/125,348 Continuation US7384983B2 (en) 2001-03-06 2005-05-09 Inhibitor of monoamine uptake

Publications (1)

Publication Number Publication Date
US20040082666A1 true US20040082666A1 (en) 2004-04-29

Family

ID=23045157

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/468,553 Abandoned US20040082666A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake
US11/125,348 Expired - Fee Related US7384983B2 (en) 2001-03-06 2005-05-09 Inhibitor of monoamine uptake

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/125,348 Expired - Fee Related US7384983B2 (en) 2001-03-06 2005-05-09 Inhibitor of monoamine uptake

Country Status (35)

Country Link
US (2) US20040082666A1 (hu)
EP (1) EP1379492B1 (hu)
JP (1) JP2004525912A (hu)
KR (1) KR20030092012A (hu)
CN (1) CN1229331C (hu)
AP (1) AP2003002855A0 (hu)
AT (2) AT414238B (hu)
AU (1) AU2002245385B2 (hu)
BR (1) BR0207716A (hu)
CA (1) CA2440161A1 (hu)
CH (1) CH695982A5 (hu)
CZ (1) CZ20032380A3 (hu)
DE (1) DE60226715D1 (hu)
DK (1) DK200301267A (hu)
EA (1) EA005768B1 (hu)
EC (1) ECSP034760A (hu)
EE (1) EE200300419A (hu)
ES (2) ES2305221T3 (hu)
FI (1) FI20031191A (hu)
GB (1) GB2389851B (hu)
HR (1) HRP20030710A2 (hu)
HU (1) HUP0303341A3 (hu)
IL (1) IL157779A0 (hu)
LT (1) LT5143B (hu)
LU (1) LU91038B1 (hu)
LV (1) LV13119B (hu)
NO (1) NO20033921L (hu)
NZ (1) NZ527431A (hu)
OA (1) OA12494A (hu)
PL (1) PL363840A1 (hu)
SE (1) SE526598C2 (hu)
SK (1) SK10632003A3 (hu)
TR (1) TR200705146T1 (hu)
WO (1) WO2002070457A1 (hu)
ZA (1) ZA200306882B (hu)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209341A1 (en) * 2001-03-06 2005-09-22 Mattiuz Edward L Inhibitor of monoamine uptake
WO2011027359A3 (en) * 2009-07-30 2011-07-14 Matrix Laboratories Ltd Process for the preparation of 4 -hydroxy atomoxetine and intermediates in the manufacture thereof
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
JP2007513945A (ja) * 2003-12-12 2007-05-31 イーライ リリー アンド カンパニー 体熱感、衝動調節障害および一般的な病状による人格変化の治療
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
MX2021004883A (es) * 2018-10-31 2021-08-05 Apnimed Inc Delaware Metodos y composiciones para tratar apnea del sue?o.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
AU642582B2 (en) * 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
AU3219800A (en) 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
ATE309196T1 (de) 1999-04-09 2005-11-15 Lilly Co Eli Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
EP1379492B1 (en) * 2001-03-06 2008-05-21 Eli Lilly And Company Inhibitor of monoamine uptake

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209341A1 (en) * 2001-03-06 2005-09-22 Mattiuz Edward L Inhibitor of monoamine uptake
US7384983B2 (en) * 2001-03-06 2008-06-10 Eli Lilly And Company Inhibitor of monoamine uptake
WO2011027359A3 (en) * 2009-07-30 2011-07-14 Matrix Laboratories Ltd Process for the preparation of 4 -hydroxy atomoxetine and intermediates in the manufacture thereof
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage

Also Published As

Publication number Publication date
LT2003075A (en) 2004-03-25
AP2003002855A0 (en) 2003-08-20
GB0323169D0 (en) 2003-11-05
CN1229331C (zh) 2005-11-30
KR20030092012A (ko) 2003-12-03
DK200301267A (da) 2003-11-06
ES2305221T3 (es) 2008-11-01
NO20033921D0 (no) 2003-09-04
CN1494526A (zh) 2004-05-05
AT414238B (de) 2006-10-15
EA005768B1 (ru) 2005-06-30
GB2389851B (en) 2005-05-25
TR200705146T1 (tr) 2008-02-21
PL363840A1 (en) 2004-11-29
LV13119B (en) 2004-06-20
NO20033921L (no) 2003-11-05
IL157779A0 (en) 2004-03-28
AU2002245385B2 (en) 2007-01-18
ATE396170T1 (de) 2008-06-15
WO2002070457A8 (en) 2004-06-03
GB2389851A (en) 2003-12-24
JP2004525912A (ja) 2004-08-26
ZA200306882B (en) 2004-12-03
EE200300419A (et) 2004-02-16
HUP0303341A3 (en) 2007-03-28
EP1379492B1 (en) 2008-05-21
SE0302361D0 (sv) 2003-09-03
SK10632003A3 (sk) 2004-06-08
EA200300978A1 (ru) 2004-02-26
DE60226715D1 (de) 2008-07-03
EP1379492A1 (en) 2004-01-14
OA12494A (en) 2006-05-24
BR0207716A (pt) 2004-03-23
LT5143B (lt) 2004-06-25
HUP0303341A2 (hu) 2004-01-28
WO2002070457A1 (en) 2002-09-12
ECSP034760A (es) 2003-10-28
LU91038B1 (fr) 2003-09-11
HRP20030710A2 (en) 2004-08-31
US20050209341A1 (en) 2005-09-22
CZ20032380A3 (en) 2004-03-17
US7384983B2 (en) 2008-06-10
ES2201942A1 (es) 2004-03-16
FI20031191A (fi) 2003-08-25
CA2440161A1 (en) 2002-09-12
SE0302361L (sv) 2003-09-03
ES2201942B2 (es) 2004-12-16
SE526598C2 (sv) 2005-10-18
ATA90422002A (de) 2006-01-15
NZ527431A (en) 2005-05-27
CH695982A5 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
US7384983B2 (en) Inhibitor of monoamine uptake
AU2002332289B2 (en) Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
FI77018C (fi) Analogifoerfarande foer framstaellning av antidepressivt aktiv (-)-enantiomer av n-metyl-n-/3-(2-metylfenoxi) -3-fenylpropyl/amin och dess farmaceutiskt godtagbara salt.
EP0288188B1 (en) 1-phenyl-3-naphthalenyloxy-propanamines
US20070032555A1 (en) Novel aryloxyphenyl-propanamines
HU226490B1 (en) Novel derivatives of 3,3-diphenylpropylamines, process for preparing them, pharmaceutical compositions containing them and methods of use them
WO2008035358A2 (en) Process for preparing dapoxetine
US7119121B2 (en) 3,3-diphenylpropylamines useful in therapy
AU2002245385A1 (en) Inhibitor of monoamine uptake
KR100192622B1 (ko) 페네타놀아민 화합물
AU2007201684A1 (en) Inhibitor of monoamine uptake
EP1633695B1 (en) Smooth muscle spasmolytic agents
US7183319B2 (en) Phenylethylamine derivatives and their use in the treatment of melanoma
PT97858A (pt) Metodo para a preparacao de um composto dicloroanilina tendo um substituinte contendo um grupo piridinilo

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE